WO2022146089A1 - 장세척을 위한 경구용 고형제제 - Google Patents

장세척을 위한 경구용 고형제제 Download PDF

Info

Publication number
WO2022146089A1
WO2022146089A1 PCT/KR2021/020327 KR2021020327W WO2022146089A1 WO 2022146089 A1 WO2022146089 A1 WO 2022146089A1 KR 2021020327 W KR2021020327 W KR 2021020327W WO 2022146089 A1 WO2022146089 A1 WO 2022146089A1
Authority
WO
WIPO (PCT)
Prior art keywords
sulfate
solid preparation
less
solid
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2021/020327
Other languages
English (en)
French (fr)
Korean (ko)
Inventor
이준엽
구완
장우영
김영운
김용준
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taejoon Pharmaceutical Co Ltd
Original Assignee
Taejoon Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taejoon Pharmaceutical Co Ltd filed Critical Taejoon Pharmaceutical Co Ltd
Priority to EP21915886.2A priority Critical patent/EP4272734A4/en
Priority to US18/270,476 priority patent/US20240075060A1/en
Priority to CN202180088680.5A priority patent/CN116801888A/zh
Priority to CA3202758A priority patent/CA3202758A1/en
Priority to JP2023539331A priority patent/JP2024501839A/ja
Publication of WO2022146089A1 publication Critical patent/WO2022146089A1/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives

Definitions

  • the present invention relates to a solid oral dosage form for bowel cleansing.
  • Colorectal cancer is one of the most common cancers worldwide, and the incidence rate is steadily increasing. Colorectal cancer is difficult to detect early because it does not show any specific symptoms, and colonoscopy is essential for early detection and diagnosis of colorectal cancer.
  • a representative bowel cleansing agent containing sulfate as an active ingredient is a suprep solution composed of 35 g of anhydrous sodium sulfate, 6.26 g of potassium sulfate, and 3.2 g of anhydrous magnesium sulfate.
  • the present invention provides an oral solid preparation comprising a laxative component as an active ingredient.
  • the oral solid preparation of the present invention may be for bowel cleansing. That is, the oral solid preparation of the present invention may be a bowel cleansing agent.
  • the solid oral dosage form includes a unit solid dosage form, and the solid unit dosage form of the oral solid dosage form may have a weight of about 0.5 g or less.
  • the unit solid preparation of the oral solid preparation may have a weight of about 0.05 g or more.
  • unit solid preparation refers to one (single) solid preparation constituting the solid preparation
  • solid preparation refers to a group including a plurality of unit solid preparations.
  • the weight of the unit solid preparation may mean the weight per unit solid preparation (pieces). That is, the solid preparation of the present invention may include unit solid preparations having a weight of about 0.5 g or less per unit solid preparation (unit). In addition, the weight per unit solid preparation (dog) may be about 0.05 g or more.
  • the solid preparation includes a plurality of unit solid preparations.
  • the solid formulation may include about 70 to about 2000 unit solid formulations. Specifically, about 70 or more, about 71 or more, about 72 or more, about 80 or more, about 86 or more, about 89 or more, about 90 or more, about 100 or more, about 107 or more of the unit solid preparation or more, about 110 or more, about 120 or more, about 125 or more, about 129 or more, about 130 or more, about 134 or more, about 140 or more, about 143 or more, about 150 or more, about 160 or more, about 161 or more, about 170 or more, about 172 or more, about 180 or more, about 188 or more, about 190 or more, about 200 or more, about 210 or more, about 215 or more, about 220 or more or more, about 230 or more, about 240 or more, about 250 or more, about 260 or more, about 270 or more, about 280 or more, about 286 or more, about 290 or
  • the weight of the unit solid preparation may be about 0.05 g or more, about 0.1 g or more, about 0.15 g or more, about 0.2 g or more, about 0.25 g or more, and about 0.5 g or less, about 0.5 g less than, about 0.4 g or less, about 0.3 g or less, about 0.25 g or less, about 0.2 g or less.
  • the weight of the unit solid preparation is about 0.05 g to about 0.5 g, about 0.1 g to about 0.5 g, about 0.1 g or more and less than about 0.5 g, about 0.1 g to about 0.4 g, about 0.05 g to about 0.4 g, from about 0.05 g to about 0.3 g, from about 0.1 g to about 0.3 g, and more specifically from about 0.1 g to about 0.2 g or from about 0.15 g to about 0.2 g.
  • the solid preparation containing the laxative component of the present invention minimizes side effects and provides convenience by setting the weight of the unit solid preparation to about 0.5 g or less, specifically less than about 0.5 g, about 0.4 g or less, and more specifically about 0.3 g or less. It is possible to increase the drug effect quickly and to show excellent intestinal cleansing power.
  • a solid formulation containing the laxative component if the weight of the unit solid formulation is higher than the above weight, when taken, dysphagia (swallowing disorder) or gastrointestinal disorders such as nausea, nausea, vomiting, and/or hyperemia of the stomach or large intestine; Side effects such as bleeding, erosion, and edema may increase significantly, and convenience and compliance may be greatly reduced.
  • the disintegration rate is greatly reduced, intestinal cleanliness may be reduced, and residues of the preparation may remain in the body, causing blurred vision. That is, within the weight range of the unit solid formulation of the solid formulation containing the laxative component as described above, a significant difference in effects may occur, such as safety (side effects), convenience of taking, medication compliance, bowel prestige, disintegration, and generation of formulation residues. have.
  • the laxative component means a component used for the purpose of excreting intestinal contents, and the laxative component is polyethylene glycol, ascorbic acid, ascorbic acid salt, sorbitol, mannitol, citric acid, citric acid salt, magnesium salt, carboxymethylcellulose, carboxyl It may include at least one selected from the group consisting of a salt of methylcellulose, lactulose, and sulfate.
  • the salt may be a pharmaceutically acceptable salt without limitation, but may be, for example, sodium, potassium, magnesium, or the like.
  • the salt of ascorbic acid may be sodium ascorbate, potassium ascorbate, magnesium ascorbate, or the like.
  • the salt of citric acid may be sodium citrate, potassium citrate, magnesium citrate, or the like.
  • the salt of carboxymethyl cellulose may be sodium carboxymethyl cellulose.
  • the magnesium salt may include at least one selected from the group consisting of magnesium oxide, heavy magnesium oxide, magnesium hydroxide, magnesium carbonate, heavy magnesium carbonate, and magnesium sulfate.
  • the sulfate may include at least one selected from the group consisting of sodium sulfate, potassium sulfate and magnesium sulfate.
  • the sulfate may be sodium sulfate and potassium sulfate.
  • the sulfate may be sodium sulfate and magnesium sulfate.
  • the sulfate may be a mixture of sodium sulfate, potassium sulfate and magnesium sulfate.
  • the sulfate may be anhydrous or hydrate, preferably the sodium sulfate or the magnesium sulfate may be anhydrous.
  • the solid formulation may include the laxative component in an amount of about 20 g or more. Specifically, the solid formulation may contain the laxative component in an amount of about 25 g or more, about 30 g or more, or about 35 g or more, but is not necessarily limited thereto. The solid formulation may contain the laxative component in an amount of about 500 g or less. Specifically, the solid formulation contains about 465 g or less, about 420 g or less, about 372 g or less, about 300 g or less, about 279 g or less, about 270 g or less, about 260 g or less, about 240 g or less, It may be included in an amount of about 230 g or less, about 200 g or less, or about 186 g or less.
  • the solid formulation contains about 150 g or less, about 140 g or less, about 130 g or less, about 120 g or less, about 110 g or less, about 100 g or less, about 93 g or less, about 90 g or less of the laxative component. , about 80 g or less, about 70 g or less, about 60 g or less, about 55 g or less, but is not necessarily limited thereto.
  • the solid formulation may include a laxative component in a total amount of about 20 to about 500 g.
  • the solid formulation may include a total of about 20 to about 420 g, about 20 to about 300 g, about 20 to about 200 g, about 20 to about 150 g of the laxative component.
  • the solid formulation comprises about 20 to about 100 g, about 20 to about 90 g, about 20 to about 80 g, about 25 to about 100 g, about 25 to about 90 g, about 25 to about the laxative component. It may include 80 g, about 25 to about 70 g, about 25 to about 60 g, about 25 to about 55 g, but is not necessarily limited thereto.
  • the solid formulation may contain a total of about 0.1 g or more, about 5 g or more, or about 10 g or more of the sulfate, and the total amount of the sulfate is about 60 g or less, about 50 g or less, about 45 g or less, may include about 40 g or less, but is not limited thereto.
  • the solid formulation may contain a total of about 0.1 to about 60 g of the sulfate. Specifically, the solid formulation may contain a total of about 5 to about 50 g of the sulfate. More specifically, the solid formulation may contain from about 5 to about 45 g of the sulfate, or from about 10 to about 40 g, but is not limited thereto.
  • the solid preparation may contain a total of about 0.1 g or more, about 5 g or more, about 10 g or more, and a total of about 450 g or less, about 300 g or less, about 250 g or less of polyethylene glycol. , about 200 g or less, about 100 g or less, about 80 g or less, about 50 g or less, about 40 g or less, but is not necessarily limited thereto.
  • the solid formulation may include a total of about 0.1 to about 450 g of the polyethylene glycol. Specifically, the solid formulation may contain a total of about 0.1 to about 300 g, and a total of about 5 to about 250 g of polyethylene glycol.
  • the solid formulation contains a total of about 10 to about 200 g, a total of about 10 to about 100 g, a total of about 10 to about 80 g, a total of about 10 to about 50 g, a total of about 10 to about 40 g of polyethylene glycol. may be included, but is not necessarily limited thereto.
  • the solid formulation may include a total of about 0.1 g or more, about 5 g or more, or about 10 g or more of the ascorbic acid and/or its salt, and a total of about 150 g or less, about 100 g or less, about 50 g or less, or about 30 g or less, but is not necessarily limited thereto.
  • the solid preparation may include a total of about 0.1 to about 150 g of the ascorbic acid and/or a salt thereof, specifically about 5 to about 100 g in total, and more specifically about 5 in total. to about 50 g, may include a total of about 10 to about 30 g, but is not necessarily limited thereto.
  • the solid formulation may include a total of about 0.1 g or more, about 5 g or more, or about 10 g or more of the sorbitol and/or mannitol, and a total of about 150 g or less, about 100 g or less , but may include about 50 g or less, but is not necessarily limited thereto.
  • the solid preparation may include a total of about 0.1 to about 150 g of the sorbitol and/or mannitol, specifically, a total of about 5 to about 100 g, more specifically, a total of about 5 to about It may include 50 g, but is not necessarily limited thereto.
  • the solid preparation may include a total of about 0.1 g or more, about 1 g or more, or about 10 g or more of the citric acid and/or a salt thereof, and a total of about 100 g or less, about 50 g
  • the solid preparation may include a total of about 0.1 to about 100 g of the citric acid and/or a salt thereof, specifically, a total of about 1 to about 50 g, more specifically, a total of about 10 to about 100 g. It may be included in an amount of about 30 g, but is not limited thereto.
  • the solid formulation may include a total of about 0.1 g or more and about 1 g or more of the magnesium salt, and may include a total of about 30 g or less and about 10 g or less, but is limited thereto. it is not going to be
  • the solid preparation may include a total of about 0.1 to about 30 g of the magnesium salt, specifically, about 1 to about 30 g, more specifically, about 1 to about 10 g in total. It may include, but is not limited to.
  • the solid preparation may include a total of about 0.1 g or more, about 0.2 g or more, and a total of about 20 g or less, about 12 g or less, about the carboxymethyl cellulose and/or its salt. It may contain 8 g or less, about 6 g or less, but is not limited thereto. In embodiments of the present invention, the solid preparation may include a total of about 0.1 to about 20 g of the carboxymethyl cellulose and/or a salt thereof, and specifically, may include a total of about 0.2 to about 6 g, However, the present invention is not limited thereto.
  • the solid formulation may contain a total of about 1 g or more, about 2 g or more, or about 5 g or more of the lactulose, and a total of about 100 g or less, about 50 g or less, about It may include 40 g or less, but is not limited thereto.
  • the solid formulation may include a total of about 1 to about 100 g of the lactulose, specifically, about 2 to about 50 g, more specifically, about 5 to about 40 g, in total. It may include, but is not limited to.
  • the content of the laxative component in the solid preparation may mean the total content of the laxative components included in a plurality of unit solid preparations included in the solid preparation.
  • the solid formulation containing the laxative component may contain the laxative component in the same amount as described above, thereby minimizing side effects while exhibiting excellent intestinal cleansing power.
  • the unit solid preparation of the present invention contains a laxative component in a total amount of about 20 mg or more, about 25 mg or more, about 30 mg or more, about 35 mg or more, about 40 mg or more, about 45 mg or more and less than about 500 mg, less than about 500 mg, less than about 450 mg, less than about 400 mg, less than about 350 mg, specifically, less than about 300 mg, less than about 295 mg, less than about 290 mg, less than about 285 mg, It may include about 280 mg or less, about 275 mg or less, or about 270 mg or less, but is not limited thereto.
  • the unit solid preparation may include about 20 mg to about 500 mg of the laxative component. In embodiments of the present invention, the unit solid preparation may include about 20 mg or more and less than 500 mg of the laxative component. Specifically, the unit solid preparation contains a total of about 20 mg to about 300 mg, about 25 mg to about 295 mg of the laxative component, more specifically, the unit solid preparation contains about 29 mg to about 290 mg of the laxative component, about 40 mg to about 290 mg, about 45 mg to about 290 mg, about 40 mg to about 295 mg, about 45 mg to about 295 mg, about 40 mg to about 285 mg, or about 45 mg to about 285 mg.
  • the unit solid preparation of the present invention contains a laxative component in about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 90% or more, about 95% or more, by weight of the unit solid preparation, It may be included in an amount of about 96% or more, about 97% or more, about 98% or more, about 99% or more, about 100% or less, or about 100% or less by weight, but is not limited thereto.
  • the unit solid preparation containing the laxative component contains the laxative component in the same amount as described above, thereby exhibiting excellent intestinal cleansing power and minimizing side effects, and may have excellent physical properties of the unit solid preparation when preparing the unit solid preparation. .
  • the solid formulation may further include simethicone.
  • the simethicone may be included in the solid formulation as an active ingredient.
  • the solid formulation may include a total of about 0.01 g to about 1.2 g of simethicone.
  • the solid formulation may contain a total of about 0.01 g or more, about 0.04 g or more, about 0.1 g or more, about 0.2 g or more, about 0.3 g or more, or about 0.4 g or more, and simethicone is about 1.2 g or less, about 1 g or less, about 0.8 g or less, about 0.6 g or less, about 0.5 g or less may be included.
  • the unit solid preparation may contain about 0.005 mg to about 17.14 mg of simethicone. Specifically, it may include about 0.04 mg to about 17.14 mg, about 0.04 mg to about 14.3 mg of simethicone. Specifically, the unit solid preparation may contain about 1 to about 2 mg of simethicone.
  • the solid formulation may further include an additional active ingredient.
  • it may further include an irritant reliever.
  • an irritant reliever for example, bisacodyl, castor oil, senna, bisoxatin, docusate, picosulfate, linaclotide, lubiprostone.
  • It may further include one or more of ingredients such as dietary fiber, bulking agent (psyllium, calcium polycarbophil, methyl cellulose, bran, etc.), anthraquinone, diphenylmethane, probiotics, and the like.
  • the present invention provides a solid oral preparation containing sulfate as an active ingredient.
  • the oral solid preparation of the present invention may be for bowel cleansing. That is, the oral solid preparation of the present invention may be a bowel cleansing agent.
  • the solid oral dosage form includes a unit solid dosage form, and the solid unit dosage form of the oral solid dosage form may have a weight of about 0.3 g or less.
  • the unit solid preparation of the oral solid preparation may have a weight of about 0.05 g or more.
  • unit solid preparation refers to one (single) solid preparation constituting the solid preparation
  • solid preparation refers to a group including a plurality of unit solid preparations.
  • the weight of the unit solid preparation may mean the weight per unit solid preparation (pieces). That is, the solid preparation containing sulfate as an active ingredient of the present invention may include unit solid preparations having a weight of about 0.3 g or less per unit solid preparation (unit). In addition, the weight per unit solid preparation (unit) of the solid preparation containing sulfate as the active ingredient may be about 0.05 g or more.
  • the solid preparation containing sulfate as an active ingredient includes a plurality of unit solid preparations containing sulfate as an active ingredient.
  • the solid preparation containing sulfate as the active ingredient may include about 80 to about 1200 unit solid preparations containing sulfate as the active ingredient.
  • the weight of the unit solid preparation containing sulfate as the active ingredient may be about 0.05 g or more, about 0.1 g or more, about 0.15 g or more, about 0.2 g or more, about 0.25 g or more, and about 0.3 g or less, about 0.25 g or less, about 0.2 g or less.
  • the weight of the unit solid preparation containing sulfate as the active ingredient may be about 0.05 g to about 0.3 g, about 0.1 g to about 0.3 g, and more specifically, about 0.1 g to about 0.2 g g, or from about 0.15 g to about 0.2 g, but is not limited thereto.
  • the solid preparation containing sulfate as the active ingredient of the present invention should have a weight of about 0.3 g or less of the unit solid preparation, so that when taken, gastrointestinal disorders such as dysphagia (swallowing disorders), nausea, nausea, vomit, or vomiting It minimizes side effects such as redness, bleeding, erosion, and edema of the stomach or large intestine, increases the convenience of taking, and enables rapid drug efficacy and excellent bowel cleansing. In addition, formulation residues may not remain in the gastrointestinal tract, and a clear view may be secured during colonoscopy.
  • gastrointestinal disorders such as dysphagia (swallowing disorders)
  • side effects such as redness, bleeding, erosion, and edema of the stomach or large intestine
  • formulation residues may not remain in the gastrointestinal tract, and a clear view may be secured during colonoscopy.
  • the solid preparation containing sulfate as the active ingredient and the unit solid preparation thereof may be a solid preparation consisting of (consisting of) sulfate as the active ingredient.
  • the solid preparation may be a solid preparation consisting of (consisting of) an active ingredient of sulfate and simethicone.
  • the sulfate may include at least one selected from the group consisting of sodium sulfate, potassium sulfate and magnesium sulfate.
  • the sulfate may include sodium sulfate.
  • the sulfate salt may include potassium sulfate.
  • the sulfate may include magnesium sulfate.
  • the sulfate may be sodium sulfate and potassium sulfate.
  • the sulfate may be sodium sulfate and magnesium sulfate.
  • the sulfate may be a mixture of sodium sulfate, potassium sulfate and magnesium sulfate.
  • the sulfate may be anhydrous or hydrate, preferably the sodium sulfate or the magnesium sulfate may be anhydrous.
  • the solid formulation containing sulfate as the active ingredient may include a total amount of the sulfate salt of about 25 g or more. Specifically, the solid formulation may contain a total amount of the sulfate salt of about 30 g or more, about 35 g or more, about 40 g or more, about 45 g or more, but is not necessarily limited thereto. The solid formulation containing sulfate as the active ingredient may contain a total amount of the sulfate salt of about 60 g or less.
  • the solid formulation may contain a total of about 55 g or less, about 50 g or less, about 45 g or less, or about 40 g or less of the sulfate salt, but is not limited thereto.
  • the solid formulation may contain a total of about 44.46 g of the sulfate salt.
  • the solid preparation containing sulfate as the active ingredient may contain a total of about 25 to about 60 g of the sulfate.
  • the solid formulation may contain a total of about 25 to about 55 g, about 30 to about 60 g, about 30 to about 55 g, or about 30 to about 50 g of the sulfate salt.
  • the solid formulation comprises a total of about 40 to about 55 g, about 40 to about 50 g, about 35 to about 50 g, about 35 to about 45 g, about 30 to about 45 g, or about 30 to about 55 g of the sulfate salt. It may include about 40 g, but is not necessarily limited thereto.
  • the solid formulation containing sulfate as the active ingredient may contain a total of about 10 g to about 60 g of sodium sulfate.
  • the solid formulation may contain a total of about 10 g or more, about 15 g or more, about 20 g or more, about 25 g or more, about 30 g or more, about 33 g or more, or about 35 g or more, and total sodium sulfate.
  • the solid formulation containing sulfate as the active ingredient may include a total of about 0.1 g to about 15 g of potassium sulfate.
  • the solid formulation contains a total of about 0.1 g or more, about 0.5 g or more, about 1 g or more, about 2 g or more, about 3 g or more, about 4 g or more, about 5 g or more, or about 6 g of potassium sulfate. or more, and may include a total of about 15 g or less, about 12 g or less, about 10 g or less, about 9 g or less, about 8 g or less, or about 7 g or less.
  • the solid formulation containing sulfate as the active ingredient may contain a total of about 0.1 g to about 8 g of magnesium sulfate.
  • the solid formulation may contain a total of about 0.1 g or more, about 0.5 g or more, about 1 g or more, about 2 g or more, about 3 g or more, or about 4 g or more, and a total of about 8 g or less, about 7 g or less, or about 6 g or less.
  • the total content of sulfate in the solid preparation containing sulfate as the active ingredient may mean the total content of sulfate contained in the plurality of unit solid preparations included in the solid preparation containing sulfate as the active ingredient.
  • the solid formulation containing sulfate as the active ingredient may contain sulfate in the same amount as above, thereby exhibiting excellent intestinal cleansing ability and minimizing side effects.
  • the unit solid preparation of the solid preparation containing sulfate as an active ingredient of the present invention may contain about 20 mg to about 300 mg of sulfate. Specifically, the unit solid preparation may contain a total amount of about 20 mg or more, about 25 mg or more, about 30 mg or more, about 35 mg or more, about 40 mg or more, about 45 mg or more, and a total of about 300 mg or less, about 295 mg or less, about 290 mg or less, about 285 mg or less, about 280 mg or less, about 275 mg or less, about 270 mg or less, but is not limited thereto.
  • the unit solid preparation of the solid preparation containing sulfate as the active ingredient may contain a total of about 25 mg to about 295 mg of the sulfate. More specifically, the unit solid preparation comprises about 29 mg to about 290 mg, about 40 mg to about 290 mg, about 45 mg to about 290 mg, about 40 mg to about 295 mg, about 45 mg to about 295 mg of the sulfate; about 40 mg to about 285 mg, or about 45 mg to about 285 mg, but is not necessarily limited thereto.
  • the unit solid preparation of a solid preparation containing sulfate as an active ingredient of the present invention contains the sulfate in about 6.7% or more, about 9% or more, about 10% or more, about 20% or more, about 30% or more, by weight of the unit solid preparation, More specifically, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 90% or more, about 95% or more, about 96% or more, about 97% or more, about It may include 98% or more, about 99% or more, about 100% or less, or about 100% or less by weight, but is not limited thereto.
  • the unit solid preparation when the sulfate includes sodium sulfate, may include about 8 mg to about 300 mg of sodium sulfate. Specifically, the unit solid preparation contains sodium sulfate at least about 8 mg, at least about 12 mg, at least about 15 mg, at least about 16 mg, at least about 20 mg, at least about 25 mg, at least about 27 mg, at least about 29 mg, It may contain about 30 mg or more, and may contain a total of about 300 mg or less, about 295 mg or less, about 290 mg or less, about 285 mg or less, about 280 mg or less, about 275 mg or less, about 270 mg or less, However, the present invention is not limited thereto.
  • the unit solid preparation contains about 8 mg to about 300 mg, about 12 mg to about 300 mg, or about 15 mg to about 300 mg of sodium sulfate, more specifically, the unit solid preparation includes sodium sulfate about 30 to about 270 mg, about 30 to about 250 mg, or about 50 to about 220 mg, more specifically, the unit solid preparation may include about 80 mg to about 170 mg of sodium sulfate, but is not limited thereto .
  • the unit solid preparation when the sulfate includes sodium sulfate, contains sodium sulfate in an amount of about 2.67% or more, about 5% or more, about 10% or more, specifically, about 12% by weight of the unit solid preparation. or more, about 16% or more, about 20% or more, about 30% or more, about 40% or more, about 60% or more, about 75% or more, about 80% or more, about 85% or more, about 90% or more, about 95% or more It may be included in an amount of more than or equal to about 100% or less than about 100% by weight, but is not limited thereto.
  • the unit solid preparation may include about 0.08 to about 187.5 mg of potassium sulfate.
  • the unit solid formulation contains potassium sulfate at about 0.08 mg or more, about 0.4 mg or more, about 0.8 mg or more, about 1 mg or more, about 2 mg or more, about 3 mg or more, about 4 mg or more, about 5 mg or more , about 9 mg or more, about 12 mg or more, and the unit solid formulation contains potassium sulfate about 187.5 mg or less, about 180 mg or less, about 170 mg or less, about 150 mg or less, about 130 mg or less, about 120 mg or less, about 100 mg or less, about 90 mg or less, about 80 mg or less, about 50 mg or less, about 40 mg or less, about 30 mg or less, but is not limited thereto.
  • the unit solid preparation contains about 2 mg to about 50 mg of potassium sulfate, specifically, the unit solid preparation contains about 5 to about 38 mg, about 9 to about 32 mg or about potassium sulfate of potassium sulfate. 12 to about 26 mg, but is not limited thereto.
  • the unit solid formulation when the sulfate includes potassium sulfate, contains potassium sulfate in about 0.01% or more, about 0.02% or more, about 0.03% or more, about 0.05% or more by weight of the unit solid formulation.
  • the unit solid preparation may include about 0.08 mg to about 100 mg of magnesium sulfate.
  • the unit solid formulation contains magnesium sulfate at least about 0.08 mg, at least about 0.4 mg, at least about 0.8 mg, at least about 1 mg, at least about 2 mg, at least about 3 mg, at least about 4 mg, at least about 6 mg.
  • the unit solid preparation contains magnesium sulfate in about 100 mg or less, about 90 mg or less, about 80 mg or less, about 70 mg or less, about 60 mg or less mg or less, about 50 mg or less, about 40 mg or less, about 30 mg or less, about 20 mg or less, about 10 mg or less, but is not limited thereto.
  • the unit solid preparation may contain about 1 mg to about 25 mg of magnesium sulfate.
  • the unit solid preparation may include about 1 to about 13 mg, about 1 to about 12 mg, or about 1 to about 10 mg of magnesium sulfate, but is not limited thereto.
  • the unit solid formulation contains magnesium sulfate at about 0.01% or more, about 0.02% or more, about 0.03% or more, about 0.05% or more of the weight of the unit solid formulation. , about 0.067% or more, about 0.08% or more, about 0.1% or more, about 0.3% or more, about 0.4% or more, about 0.5% or more, about 0.8% or more, about 1% or more, about 1.5% or more, about 2% or more , about 3% or more, about 4% or more, about 5% or more, about 10% or more, about 20% or more, about 30% or more, about 32% or less by weight, but not limited thereto it is not
  • the unit solid preparation containing sulfate as the active ingredient contains sulfate in the same amount as described above, and can minimize side effects while exhibiting excellent intestinal cleansing ability, and when preparing the unit solid preparation, the physical properties of the unit solid preparation can be excellent. have.
  • the solid formulation containing sulfate as the active ingredient may further include simethicone.
  • the simethicone may be included in the solid formulation as an active ingredient.
  • the solid formulation containing sulfate as the active ingredient may contain a total of about 0.01 g to about 1.2 g of simethicone.
  • the solid formulation may contain a total of about 0.01 g or more, about 0.04 g or more, about 0.1 g or more, about 0.2 g or more, about 0.3 g or more, or about 0.4 g or more, and simethicone is about 1.2 g or less, about 1 g or less, about 0.8 g or less, about 0.6 g or less, about 0.5 g or less may be included.
  • the unit solid preparation of the solid preparation containing sulfate as the active ingredient may contain about 0.008 mg to about 15 mg of simethicone.
  • the unit solid preparation may contain simethicone at least about 0.008 mg, at least about 0.01 mg, at least about 0.05 mg, at least about 0.1 mg, at least about 0.5 mg, at least about 1 mg, and at least about 15 simethicone. mg or less, about 12.5 mg or less, about 10 mg or less, about 8 mg or less, about 6 mg or less, but is not limited thereto.
  • the unit solid preparation contains about 0.04 mg to about 15 mg of simethicone, and more specifically, the unit solid preparation may contain about 1 to about 2 mg of simethicone, but is limited thereto. it is not going to be
  • the solid preparation and unit solid preparation containing sulfate as an active ingredient of the present invention may refer to a solid preparation and unit solid preparation composed (consisting of) sulfate or sulfate and simethicone as an active ingredient.
  • a solid preparation and unit solid preparation composed (consisting of) sulfate or sulfate and simethicone as an active ingredient.
  • the active ingredient is sulfate or sulfate and simethicone
  • side effects are minimized at a weight of about 0.3 g or less of the unit solid formulation, and it can exhibit excellent intestinal cleansing power while increasing the convenience of taking the unit.
  • the weight is higher than about 0.3 g, side effects are significantly increased, and there may be significant differences in effects such as safety (side effects), convenience of taking, compliance with medication, intestinal prep strength, disintegration, and generation of product residues.
  • active ingredient has the same meaning as the active ingredient, and the active ingredient may also be referred to as an active ingredient.
  • solid preparation for oral administration has the same meaning as a solid preparation for oral administration, and may also be referred to as a solid preparation for oral administration.
  • the solid preparation of the present invention further includes a pharmaceutically acceptable additive.
  • additives may refer to ingredients that do not impair the effects of active ingredients.
  • the additives are, for example, fillers, disintegrants, binders, plasticizers, lubricants, coating agents, pH adjusters, diluents, lubricants, preservatives, buffers, sweeteners, wetting agents, suspending agents, colorants, fragrances, excipients, etc. are conventional in each formulation. Any pharmaceutically acceptable ones used as
  • the additive may be a known additive.
  • the disintegrant may be crospovidone, guar gum, xanthan gum, sodium starch glycolate, low-substituted hydroxypropyl cellulose, croscarmellose sodium, microcrystalline cellulose, dextran, mannitol, or mixtures thereof.
  • the present invention is not limited thereto.
  • the binder is alginic acid, sodium alginate, carbomer, copovidone, starch, polyethylene glycol, polyvinylpyrrolidone, polyvinyl derivative, microcrystalline cellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxy Propyl cellulose, low-substituted hydroxypropyl cellulose, hydroxypropyl methyl cellulose, or a mixture thereof may be used, but is not limited thereto.
  • the lubricant may include stearic acid, stearate, stearyl fumarate, lauryl sulfate, stearyl sulfate, vegetable oil, polyethylene glycol, poloxamer, caprylic acid salt, or a mixture thereof, but is limited thereto. it is not going to be
  • the coating agent is polyvinyl alcohol/polyethylene glycol copolymer, amino methacrylate copolymer, methyl methacrylate copolymer, sucrose, hypromellose, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, carboxymethyl Cellulose, hydroxypropyl cellulose, polyethylene glycol, ethyl cellulose, or a mixture thereof may be used, but is not limited thereto.
  • the unit solid preparation of the present invention may have a circular or oval shape, but is not necessarily limited thereto.
  • the diameter or length of the unit solid preparation may be about 1 mm to about 20 mm, about 1 mm to about 15 mm, specifically to about 1 to about 12 mm, and may be from about 1 to about 10 mm, but is not necessarily limited thereto.
  • the thickness or height of the unit solid preparation may be about 1 mm to about 10 mm, and specifically, about 1 to about 5 mm. However, it is not necessarily limited thereto.
  • the form of the unit solid preparation may be a tablet, pellet, capsule or pill, and the solid preparation is a unit solid preparation in the form of a tablet, pellet, capsule, or pill, or any of these It may include a combination of
  • the unit solid preparation is a tablet, and the solid preparation may include a unit solid preparation in the form of a tablet.
  • the tablet may be an uncoated tablet or a coated tablet.
  • the oral solid preparation of the present invention can be prepared by an appropriate method according to the specific dosage form.
  • the solid preparation when it is prepared in the form of a tablet, it may be prepared using a granulation process, a mixing process, and/or a tableting process.
  • the granulation process may be appropriately selected from a dry granulation method, a wet granulation method, and a coating method.
  • the unit solid preparation of the present invention may be prepared in a weight of about 0.05 g or more, and more specifically, a weight of about 0.1 g or more, thereby improving production efficiency.
  • the unit solid preparation of the present invention can be easily prepared and can have excellent physical properties as a solid preparation.
  • the unit solid preparation of the present invention has the same weight as described above, so it does not get caught in the esophagus or feel a foreign body when taken, and gastrointestinal such as dysphagia (swallowing disorder), nausea, nausea, vomit, and vomiting Side effects such as disability can be minimized.
  • side effects such as redness, bleeding, erosion, and edema in the stomach or large intestine can be minimized when taken. Therefore, the solid preparation of the present invention can successfully complete the administration because of its excellent convenience and adherence to administration, exhibit an excellent intestinal cleansing effect, and minimize side effects associated with administration.
  • the solid formulation may not leave a formulation residue in the gastrointestinal tract, and it may be possible to secure a clear view during colonoscopy.
  • the solid oral dosage form of the present invention may be administered at all of the total dose at one time point (referred to as non-divided administration or divided administration on the same day) or divided into several time points (referred to as divided administration or divided administration over two days).
  • the oral solid preparation of the present invention may be taken over several hours in the evening on the eve of the test or in the morning of the test day. Specifically, a portion of the total dose may be taken and the remainder may be taken after a period of time, for example, from about 0.5 to about 3 hours.
  • a portion of the oral solid formulation of the present invention may be taken the evening before the test, and the remainder may be taken in the morning of the test day.
  • each dose can be taken within a specific time. Specifically, each dose may be taken within about 2 hours, within about 1 hour, or within about 30 minutes.
  • the oral solid preparation of the present invention can be taken with about 1L or more of water. Specifically, it can be taken with about 2L or more of water.
  • the oral solid preparation of the present invention may be taken together with about 1 to 4 L, or about 2 to 3 L of water.
  • the oral solid preparation of the present invention is a solid oral preparation containing (1) sulfate as an active ingredient, and having a weight of about 0.3 g or less per unit solid preparation.
  • sulfate includes at least one selected from the group consisting of sodium sulfate, potassium sulfate and magnesium sulfate.
  • the oral solid preparation of the present invention is an oral solid preparation comprising (i) a laxative component as an active ingredient, and having a weight of about 0.5 g or less per unit solid preparation.
  • the solid oral dosage form according to any one of (i) and (ii) above, wherein the oral solid preparation contains polyethylene glycol, ascorbic acid, salts of ascorbic acid, sorbitol, mannitol, citric acid, salts of citric acid, and magnesium salts as a laxative component for the large intestine. , carboxymethylcellulose, a salt of carboxymethylcellulose, lactulose, and at least one selected from the group consisting of sulfate, it is an oral solid preparation.
  • the present invention also provides a method for washing the intestines comprising administering (effective amount of) the oral solid preparation of the present invention.
  • the present invention also provides the use of the oral solid preparation of the present invention for bowel cleansing.
  • the oral solid preparation of the present invention is the same as described in the oral solid preparation of the present invention.
  • the oral solid preparation of the present invention can minimize side effects such as dysphagia (swallowing disorder), nausea, and gastrointestinal disorders such as nausea, and has excellent dosing convenience and medication compliance.
  • the solid preparation of the present invention rapidly disintegrates and dissolves, and side effects such as congestion, bleeding, erosion, and edema in the stomach are reduced, and the drug effect can be rapidly expressed.
  • the completion time can be shortened.
  • Tablets were prepared according to the ingredients and contents of Table 1 below. Specifically, after mixing 109.375 g of anhydrous sodium sulfate, 19.563 g of potassium sulfate, 10 g of anhydrous magnesium sulfate, and 4.663 g of copovidone, 1 mL of purified water is slowly added to the mixture and mixed. After sieving the mixture through a 20 mesh, add 1.4 g of stearic acid and mix. It was tableted with a tablet press.
  • Example 1 Comparative Example 1 (mg) Anhydrous sodium sulfate 109.375 1093.75 potassium sulfate 19.563 195.63 Anhydrous magnesium sulfate 10.000 100.00 copovidone 4.663 46.63 stearic acid 1.400 14.00 1 tablet weight (mg) 145.0 1450.0
  • the disintegration time of the tablets of Example 1 and Comparative Example 1 prepared above was measured in water according to the disintegration test method of the Korean Pharmacopoeia.
  • Example 1 The disintegration times of the tablets of Example 1 and Comparative Example 1 were 7 minutes 20 seconds and 17 minutes 30 seconds, respectively, confirming that the Example 1 tablet disintegrated much faster. It was confirmed that the tablet of Example 1, which disintegrates rapidly, is more suitable as a solid bowel cleansing agent.
  • Tablets were prepared according to the ingredients and contents of Table 2 below. Specifically, 109.375 g of anhydrous sodium sulfate, 19.563 g of potassium sulfate, 10 g of anhydrous magnesium sulfate, and 5.062 g of copovidone are mixed, and then 3 mL of purified water is slowly administered and mixed. After sieving the mixture through a 20 mesh, 1.5 g of stearic acid is added and mixed. It was tableted with a tablet press. After that, the polyethylene glycol-polyvinyl alcohol copolymer was dissolved in purified water at a concentration of 5%, and then film coating was performed with a coating machine.
  • Example 2 Comparative Example 2 (mg) Anhydrous sodium sulfate 109.375 1093.75 potassium sulfate 19.563 195.63 Anhydrous magnesium sulfate 10.00 100.00 copovidone 5.062 50.62 stearic acid 1.50 15.00 Polyethylene glycol polyvinyl alcohol copolymer 3.00 30.00 1 tablet weight (mg) 148.50 1485.00
  • the dissolution time of 30 tablets of Example 2 and 3 tablets of Comparative Example 2 was measured by the paddle method at about 37° C., 50 rpm, and 900 ml of pH 1.2 eluate (dissolution device Pharmatest).
  • the tablets of Example 2 and Comparative Example 2 were evaluated by putting 10 tablets and 1 tablet each in a vessel. The elution rate was analyzed by liquid chromatogram (HPLC).
  • Example 2 all eluted within 15 minutes, whereas the tablets of Comparative Example 2 all eluted within about 30 minutes. It can be seen that the Example 2 tablet is much more preferable as a solid bowel cleansing agent than the Comparative Example 2 tablet.
  • Tablets of Example 3 and Comparative Example 3 were prepared according to the components and contents of Table 3 below. Specifically, 123.15 g of polyethylene glycol 3350, 5.79 g of ascorbic acid, 7.27 g of sodium ascorbate, 9.24 g of anhydrous sodium sulfate, 3.31 g of sodium chloride, and 1.24 g of potassium chloride were sieved through a 20 mesh, mixed and compressed with a tablet press to prepare tablets.
  • Example 3 Comparative Example 3 (mg) Polyethylene glycol 3350 123.15 1231.5 ascorbic acid 5.79 57.9 sodium ascorbate 7.27 72.7 Anhydrous sodium sulfate 9.24 92.4 sodium chloride 3.31 33.1 potassium chloride 1.24 12.4 1 tablet weight (mg) 150 1500
  • the disintegration time of the tablets of Example 3 and Comparative Example 3 prepared above was measured in water according to the disintegration test method of the Korean Pharmacopoeia.
  • Example 3 and Comparative Example 3 were 5 minutes 45 seconds and 15 minutes 50 seconds, respectively, confirming that the Example 3 tablet disintegrated much faster. It was confirmed that the rapidly disintegrating Example 3 tablet was more suitable as a solid bowel cleansing agent.
  • tablets were prepared according to the components and contents in Table 4 below. Specifically, 109.375 g of anhydrous sodium sulfate, 19.563 g of potassium sulfate, 10 g of anhydrous magnesium sulfate, and 5.062 g of copovidone are mixed, and then 3 mL of purified water is slowly administered and mixed. After sieving the mixture through a 20 mesh, 1.5 g of stearic acid is added and mixed. It was tableted with a tablet press. After that, the polyethylene glycol-polyvinyl alcohol copolymer was dissolved in a 50% ethanol solution at a concentration of 10%, followed by film coating with a coating machine.
  • Tablet 1 (mg) Tablet 2 (mg) tablet 3 (mg) Anhydrous sodium sulfate 109.375 218.75 1093.75 potassium sulfate 19.563 39.125 195.625 Anhydrous magnesium sulfate 10.00 20.00 100.00 copovidone 5.062 10.125 50.625 stearic acid 1.50 3.00 15.00 Polyethylene glycol polyvinyl alcohol copolymer 3.00 6.00 30.00 1 tablet weight (mg) 148.50 297.00 1485.00
  • tablets 1 and 2 according to the present invention can improve side effects.
  • Tablets 1 to 3 of Table 4 By administering the tablets 1 to 3 of Table 4, the occurrence of side effects (edema) in the gastrointestinal tract was evaluated through histological examination. Tablets 1 to 3 were prepared, administered to three beagles, respectively, and a series of procedures for incision of the stomach were the same as in Experimental Example 4. Hematoxylin & Eosin (H&E) staining was performed after taking tissue from the incised stomach and preparing a specimen for biopsy, and the occurrence of edema was observed using an optical microscope.
  • H&E Hematoxylin & Eosin
  • tablets 1 and 2 according to the present invention can improve side effects.
  • Tablets 1 and 3 of Table 4 were administered to a beagle to compare dosing convenience. 80 tablets 1 and 8 tablets 3 were administered without anesthesia of a beagle (about 10 kg), and it was observed whether administration was possible without problems such as swallowing disorders.
  • Tablet 3 it is difficult to swallow, so the experimenter has to forcefully push the tablet to the throat area to be administered. It has been observed to swallow itself. Through this, it can be seen that although tablet 1 of the present invention has approximately 10 times more tablets to be taken compared to tablet 3 having a similar weight to that of a commercially available product, it can be taken much more easily.
  • Tablets were prepared according to the ingredients and contents of Table 6 below. Specifically, for Tablet 4, after mixing 138.938 g of anhydrous sodium sulfate, 4.663 g of copovidone, and 2.4 g of D-mannitol, 0.7 mL of purified water is slowly administered and mixed, and the mixture is sieved through a 20 mesh, and 1.0 g of stearic acid is added and mixed, and then mixed with a tableting machine. was tableted with After that, the polyethylene glycol/polyvinyl alcohol copolymer was dissolved in a 50% ethanol solution at a concentration of 10%, and then film coating was performed with a coating machine.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/KR2021/020327 2020-12-31 2021-12-30 장세척을 위한 경구용 고형제제 Ceased WO2022146089A1 (ko)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP21915886.2A EP4272734A4 (en) 2020-12-31 2021-12-30 SOLID ORAL FORMULATION FOR COLON CLEANSING
US18/270,476 US20240075060A1 (en) 2020-12-31 2021-12-30 Oral solid formulation for colon cleansing
CN202180088680.5A CN116801888A (zh) 2020-12-31 2021-12-30 用于结肠清洁的口服固体制剂
CA3202758A CA3202758A1 (en) 2020-12-31 2021-12-30 Oral solid formulation for colon cleansing
JP2023539331A JP2024501839A (ja) 2020-12-31 2021-12-30 腸管洗浄用の経口固形製剤

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2020-0189688 2020-12-31
KR20200189689 2020-12-31
KR10-2020-0189689 2020-12-31
KR20200189688 2020-12-31

Publications (1)

Publication Number Publication Date
WO2022146089A1 true WO2022146089A1 (ko) 2022-07-07

Family

ID=82259801

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/020327 Ceased WO2022146089A1 (ko) 2020-12-31 2021-12-30 장세척을 위한 경구용 고형제제

Country Status (6)

Country Link
US (1) US20240075060A1 (cg-RX-API-DMAC7.html)
EP (1) EP4272734A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024501839A (cg-RX-API-DMAC7.html)
KR (2) KR102669683B1 (cg-RX-API-DMAC7.html)
CA (1) CA3202758A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022146089A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102635438B1 (ko) * 2022-10-07 2024-02-13 주식회사태준제약 장 세척을 위한 고형제제 및 이의 제조방법
TW202508608A (zh) * 2023-05-12 2025-03-01 南韓商法姆拜歐韓國股份有限公司 結腸緩瀉錠劑及包含彼之結腸緩瀉劑
WO2025259039A1 (ko) * 2024-06-13 2025-12-18 주식회사태준제약 장정결을 위한 고형제제

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018610A1 (en) * 1996-10-28 1998-05-07 Lengerich Bernhard H Van Embedding and encapsulation of controlled release particles
WO2007099398A2 (en) * 2005-09-27 2007-09-07 Naturalite Benelux B.V. Methods and compositions for treatment of skin
KR20140018210A (ko) * 2010-12-13 2014-02-12 토마스 줄리어스 보로디 위 및 결장 조제물 및 이의 제조 및 사용 방법
KR20140044628A (ko) * 2012-10-05 2014-04-15 주식회사태준제약 신규한 폴리에틸렌글리콜과 비타민 씨를 함유하는 안정성이 개선된 장관 하제 조성물
JP2016537404A (ja) * 2013-10-17 2016-12-01 カン, ユンシクKANG, Yoon Sik 腸洗浄用組成物
KR20190041233A (ko) * 2017-10-12 2019-04-22 주식회사 한국팜비오 황산염을 포함하는 대장 하제 조성물
KR20190093501A (ko) * 2018-02-01 2019-08-09 주식회사태준제약 장세척 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR590701A0 (en) * 2001-06-25 2001-07-19 Colocaps Pty Ltd Laxative preparation
JP2008115085A (ja) * 2006-11-01 2008-05-22 Tendou Seiyaku Kk 緩下剤
US20130189377A1 (en) * 2010-07-27 2013-07-25 Norgine Bv Compositions
KR101659746B1 (ko) * 2014-01-28 2016-09-26 주식회사한국파마 황산염을 함유하는 장관 하제 조성물 및 이의 제조 방법
KR20180091572A (ko) * 2017-02-07 2018-08-16 주식회사 한국팜비오 경구투여용 대장하제조성물
KR102111094B1 (ko) * 2018-06-18 2020-05-14 주식회사 한국팜비오 무수황산나트륨, 황산칼륨, 무수황산마그네슘 및 시메티콘을 포함하는 장관하제 경구투여용 고형제제 조성물

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018610A1 (en) * 1996-10-28 1998-05-07 Lengerich Bernhard H Van Embedding and encapsulation of controlled release particles
WO2007099398A2 (en) * 2005-09-27 2007-09-07 Naturalite Benelux B.V. Methods and compositions for treatment of skin
KR20140018210A (ko) * 2010-12-13 2014-02-12 토마스 줄리어스 보로디 위 및 결장 조제물 및 이의 제조 및 사용 방법
KR20140044628A (ko) * 2012-10-05 2014-04-15 주식회사태준제약 신규한 폴리에틸렌글리콜과 비타민 씨를 함유하는 안정성이 개선된 장관 하제 조성물
JP2016537404A (ja) * 2013-10-17 2016-12-01 カン, ユンシクKANG, Yoon Sik 腸洗浄用組成物
KR20190041233A (ko) * 2017-10-12 2019-04-22 주식회사 한국팜비오 황산염을 포함하는 대장 하제 조성물
KR20190093501A (ko) * 2018-02-01 2019-08-09 주식회사태준제약 장세척 조성물

Also Published As

Publication number Publication date
KR102669683B1 (ko) 2024-05-28
EP4272734A4 (en) 2024-12-04
EP4272734A1 (en) 2023-11-08
KR20220097340A (ko) 2022-07-07
US20240075060A1 (en) 2024-03-07
CA3202758A1 (en) 2022-07-07
KR20230043086A (ko) 2023-03-30
JP2024501839A (ja) 2024-01-16

Similar Documents

Publication Publication Date Title
KR100777169B1 (ko) 5-메틸-1-페닐-2-(1ｈ)-피리돈을 활성 성분으로서함유하는 의약 제제
WO2020040438A1 (ko) 에스오메프라졸 및 탄산수소나트륨을 포함하는 우수한 방출특성을 갖는 약제학적 제제
WO2018111002A1 (ko) 카바메이트 화합물을 포함하는 구강 붕해 정제
KR20230043086A (ko) 장세척을 위한 경구용 고형제제
WO2017119801A1 (ko) 바레니클린 또는 이의 약학적으로 허용가능한 염을 함유하는 맛 차폐된 구강 투여용 약학 제제
WO2020017808A1 (ko) 날푸라핀 함유 구강붕해정
WO2011152652A2 (ko) 1일 1회 투여로 최적의 약리학적 임상 효과를 제공하는 아세클로페낙 서방성 제제
WO2018097629A1 (ko) 바레니클린 서방성 제제 및 이의 제조 방법
WO2020242132A1 (ko) 디메틸푸마르산염을 함유한 장용성 정제
WO2014054880A1 (ko) 신규한 폴리에틸렌글리콜과 비타민 씨를 함유하는 안정성이 개선된 장관 하제 조성물
US7943585B2 (en) Extended release antibiotic composition
WO2022086238A1 (en) Orally disintegrating tablet comprising benzimidazole derivative compound and preparation method thereof
WO2012148181A2 (ko) 약물 방출제어용 조성물
WO2016013795A1 (ko) 서방성 제제
WO2024237610A1 (ko) 대장 하제 정제 및 이를 포함하는 대장 하제
WO2016137266A2 (ko) 에페리손과 펠루비프로펜을 함유하는 약제학적 조성물
WO2021080184A1 (ko) 콜린알포세레이트를 포함하는 소형 형태의 서방성 약학조성물
EP2648730A2 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
WO2013169082A1 (ko) 보센탄 제어방출성 경구제제
WO2013119002A1 (ko) 폴리에틸렌글리콜과 비타민 씨를 함유하는 장관 하제 조성물
WO2025259039A1 (ko) 장정결을 위한 고형제제
WO2014157852A1 (ko) 활성 성분으로 에페리손을 함유하는 서방성 제제 조성물
WO2014163215A1 (ko) 쓴 맛이 차폐된 약제학적 조성물
WO2010008224A2 (ko) 안정성이 개선된 암로디핀 속붕해성 정제 및 그의 제조 방법
CN116801888A (zh) 用于结肠清洁的口服固体制剂

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21915886

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3202758

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2023539331

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 202180088680.5

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021915886

Country of ref document: EP

Effective date: 20230731